Anandamide inhibits the Wnt/β-catenin signalling pathway in human breast cancer MDA MB 231 cells.
Comment in
- PMID:
23434151
[PubMed – indexed for MEDLINE]
Our studies have demonstrated that the activation of cannabinoid CB1 receptors inhibited the growth of an adenocarcinoma breast cancer cell line, MDA MB 231 cells.1 Recently it has been showed that the constitutive Wnt pathway activation, as evidenced by accumulation of active form of β-catenin in the nuclei, was only observed in a few invasive breast carcinoma cell lines, including MDA MB 231 cells.2 We described that the CB1 activation by methyl-F-anandamide (Met-F-AEA), a stable analogue of the anandamide, treatment decreased the protein level of β-catenin in nuclei of MDA MB 231 cells thus inhibiting the transcription of proliferation-associated genes.
Publication Types, MeSH Terms, Substances
Publication Types
MeSH Terms
- Arachidonic Acids/pharmacology*
- Breast Neoplasms/metabolism
- Breast Neoplasms/pathology
- Cannabinoid Receptor Agonists/pharmacology
- Cell Line, Tumor
- Cell Proliferation/drug effects
- Endocannabinoids/pharmacology*
- Epithelial-Mesenchymal Transition/drug effects
- Female
- Humans
- Polyunsaturated Alkamides/pharmacology*
- Wnt Signaling Pathway/drug effects*
- beta Catenin/metabolism
Substances
LinkOut – more resources
Full Text Sources
Other Literature Sources
Medical